A Pivotal Legal Battle Looms for Bayer's Finances

U.S. Supreme Court hearing in April may undermine 65,000 Roundup lawsuits. Bayer's 2025 net loss hit €3.6B due to litigation, with stock deeply oversold ahead of verdict.

Bayer AG faces a defining moment in its long-running legal saga this spring, with a U.S. Supreme Court hearing poised to significantly alter the financial outlook for the German pharmaceutical and agricultural giant. The outcome could determine the scale of its liabilities concerning the herbicide Roundup.

Supreme Court to Hear Critical Case

The focal point is the case of Monsanto v. Durnell, scheduled for oral arguments on April 27. The nation's highest court will consider a legal defense asserting that federal law preempts state-level lawsuits which allege a failure to warn about cancer risks. Since the U.S. Environmental Protection Agency (EPA) does not mandate cancer warnings for glyphosate, Roundup's active ingredient, Bayer contends these claims are invalid. A ruling in the company's favor, expected in the latter half of June, could undermine the legal foundation for approximately 65,000 pending lawsuits from plaintiffs with Non-Hodgkin Lymphoma.

Concurrently, agricultural industry groups are advocating for "Shield Laws" at the state level, designed to protect companies from similar litigation waves. The state of Georgia has already enacted such legislation.

Financial Strain from Mounting Litigation

The substantial burden of these legal challenges is clearly reflected in Bayer's recent financial performance. For 2025, the company reported an adjusted EBITDA of nearly €9.7 billion, indicating a robust underlying operational business. However, net income plummeted to a loss of €3.6 billion, dragged down by litigation provisions. Management further anticipates a negative free cash flow for 2026, citing expected settlement payments.

This profound uncertainty continues to weigh heavily on investor sentiment. The stock closed yesterday's session at €38.50. With a Relative Strength Index (RSI) reading of 16.5, the shares are technically considered deeply oversold, highlighting persistent market caution ahead of the court proceedings.

Key Dates for Shareholders

Investors face two crucial events in quick succession. The Annual General Meeting is set for April 24, where a dividend proposal of €0.11 per share for the past fiscal year will be put to a vote. Merely three days later, on April 27, the Supreme Court hearing will commence. The verdict from this legal battle is likely to shape the conglomerate's financial structure for years to come.